Healthcare provider profile · identity verified

Larry Wayne Spector, D.O.

Allopathic & Osteopathic Physicians|Internal Medicine · ELKINS PARK, PA · NPI 1780613398

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Larry Wayne Spector, D.O. received $7,743.88 in general payments during 2025 across 13 reported records.

Lilly USA, LLC accounted for 76.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Lokelma by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$7,743.88

13 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$5,948.94	76.8%	7	2025
Regeneron Healthcare Solutions, Inc.	Unresolved — no canonical attribution shown	$1,664.00	21.5%	4	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$115.00	1.5%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$15.94	0.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Consulting Fee	$7,289.00	7
Food and Beverage	$238.97	5
Travel and Lodging	$215.91	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$1,877.28	2	2025
Source payment records 2025-09-21 · Lilly USA, LLC · $77.28 · Open Payments source 2025-10-08 · Lilly USA, LLC · $1,800.00 · Open Payments source
DUPIXENT Normalized: dupixent	Biological	Regeneron Healthcare Solutions, Inc.	$1,664.00	4	2025
Source payment records 2025-11-21 · Regeneron Healthcare Solutions, Inc. · $104.00 · Open Payments source 2025-11-21 · Regeneron Healthcare Solutions, Inc. · $104.00 · Open Payments source 2025-11-21 · Regeneron Healthcare Solutions, Inc. · $208.00 · Open Payments source 2025-11-21 · Regeneron Healthcare Solutions, Inc. · $1,248.00 · Open Payments source
KRYSTEXXA Normalized: krystexxa	Biological	Amgen Inc.	$115.00	1	2025
Source payment records 2025-03-14 · Amgen Inc. · $115.00 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$15.94	1	2025
Source payment records 2025-01-09 · AstraZeneca Pharmaceuticals LP · $15.94 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	40	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	55	24
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	LOKELMA open payments reported associated product	CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624	Lokelma · 2024 Exact normalized brand match · 1 Part D row	33	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	43	17
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	52	15

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1247	354
Eliquis	Apixaban	618	147
Pantoprazole Sodium	Pantoprazole Sodium	601	206
Gabapentin	Gabapentin	583	173
Amlodipine Besylate	Amlodipine Besylate	551	163
Furosemide	Furosemide	468	137
Levothyroxine Sodium	Levothyroxine Sodium	448	118
Metoprolol Tartrate	Metoprolol Tartrate	393	93
Tamsulosin Hcl	Tamsulosin Hcl	388	121
Mirtazapine	Mirtazapine	356	93
Metoprolol Succinate	Metoprolol Succinate	323	109
Losartan Potassium	Losartan Potassium	302	105
Trazodone Hcl	Trazodone Hcl	276	64
Carvedilol	Carvedilol	273	102
Sertraline Hcl	Sertraline Hcl	225	59
Clopidogrel	Clopidogrel Bisulfate	218	58
Metformin Hcl	Metformin Hcl	206	79
Albuterol Sulfate Hfa	Albuterol Sulfate	205	115
Potassium Chloride	Potassium Chloride	194	60
Omeprazole	Omeprazole	183	73
Fluticasone Propionate	Fluticasone Propionate	171	83
Lisinopril	Lisinopril	169	61
Ondansetron Hcl	Ondansetron Hcl	163	53
Escitalopram Oxalate	Escitalopram Oxalate	158	45
Famotidine	Famotidine	154	60
Duloxetine Hcl	Duloxetine Hcl	153	48
Allopurinol	Allopurinol	150	35
Donepezil Hcl	Donepezil Hcl	149	32
Simvastatin	Simvastatin	146	29
Montelukast Sodium	Montelukast Sodium	141	52
Xarelto	Rivaroxaban	135	22
Entresto	Sacubitril/Valsartan	131	16
Levetiracetam	Levetiracetam	130	31
Quetiapine Fumarate	Quetiapine Fumarate	127	39
Baclofen	Baclofen	124	26
Nifedipine Er	Nifedipine	118	47
Latanoprost	Latanoprost	116	39
Hydralazine Hcl	Hydralazine Hcl	111	33
Diclofenac Sodium	Diclofenac Sodium	105	64
Finasteride	Finasteride	101	29
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	100	33
Rosuvastatin Calcium	Rosuvastatin Calcium	89	41
Ezetimibe	Ezetimibe	85	30
Enoxaparin Sodium	Enoxaparin Sodium	82	32
Isosorbide Mononitrate Er	Isosorbide Mononitrate	82	26
Risperidone	Risperidone	81	23
Albuterol Sulfate	Albuterol Sulfate	79	50
Carbidopa-Levodopa	Carbidopa/Levodopa	79	17
Memantine Hcl	Memantine Hcl	79	13
Spironolactone	Spironolactone	79	26
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	78	30
Prednisone	Prednisone	74	39
Amiodarone Hcl	Amiodarone Hcl	73	32
Bumetanide	Bumetanide	71	33
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	71	49
Alendronate Sodium	Alendronate Sodium	70	23
Olanzapine	Olanzapine	70	suppressed
Divalproex Sodium	Divalproex Sodium	69	18
Tizanidine Hcl	Tizanidine Hcl	69	22
Insulin Lispro Kwikpen U-100	Insulin Lispro	65	55
Pravastatin Sodium	Pravastatin Sodium	65	22
Triamcinolone Acetonide	Triamcinolone Acetonide	64	27
Buspirone Hcl	Buspirone Hcl	63	25
Midodrine Hcl	Midodrine Hcl	62	21
Citalopram Hbr	Citalopram Hydrobromide	59	15
Oxybutynin Chloride Er	Oxybutynin Chloride	56	16
Aripiprazole	Aripiprazole	55	20
Comfort Ez Pen Needle	Pen Needle, Diabetic	55	40
Farxiga	Dapagliflozin Propanediol	55	24
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	55	16
Santyl	Collagenase Clostridium Hist.	55	37
Valsartan	Valsartan	54	26
Atenolol	Atenolol	53	14
Sucralfate	Sucralfate	53	suppressed
Trulicity	Dulaglutide	52	15
Ammonium Lactate	Ammonium Lactate	50	37
Vascepa	Icosapent Ethyl	50	suppressed
Gemtesa	Vibegron	48	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	46	15
Valproic Acid	Valproic Acid (As Sodium Salt)	44	suppressed
Anastrozole	Anastrozole	43	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	17
Jardiance	Empagliflozin	43	17
Nystatin	Nystatin	43	26
Brilinta	Ticagrelor	40	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	40	18
Diltiazem Hcl	Diltiazem Hcl	39	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	38	13
Flecainide Acetate	Flecainide Acetate	38	suppressed
Hydrocortisone	Hydrocortisone	37	17
Hydroxyzine Hcl	Hydroxyzine Hcl	37	13
Januvia	Sitagliptin Phosphate	37	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	36	26
Oxybutynin Chloride	Oxybutynin Chloride	34	15
Pregabalin	Pregabalin	34	19
Sevelamer Carbonate	Sevelamer Carbonate	34	15
Budesonide	Budesonide	33	16
Clonidine Hcl	Clonidine Hcl	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	13
Lokelma	Sodium Zirconium Cyclosilicate	33	suppressed
Primidone	Primidone	33	suppressed
Benztropine Mesylate	Benztropine Mesylate	32	11
Ibuprofen	Ibuprofen	32	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	18
Loperamide	Loperamide Hcl	32	20
Vancomycin Hcl	Vancomycin Hcl	32	suppressed
Klor-Con M20	Potassium Chloride	31	suppressed
Methenamine Hippurate	Methenamine Hippurate	31	suppressed
Calcium Acetate	Calcium Acetate	30	14
Topiramate	Topiramate	30	15
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	29	11
Bupropion Hcl Sr	Bupropion Hcl	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	29	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	28	22
Lantus	Insulin Glargine,hum.Rec.Anlog	28	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	15
Warfarin Sodium	Warfarin Sodium	28	suppressed
Celecoxib	Celecoxib	27	14
Glipizide	Glipizide	27	13
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	27	20
Venlafaxine Hcl	Venlafaxine Hcl	27	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	12
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	26	suppressed
Invokana	Canagliflozin	26	suppressed
Nitroglycerin	Nitroglycerin	26	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	15
Linzess	Linaclotide	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Mupirocin	Mupirocin	24	19
Myrbetriq	Mirabegron	24	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	24	16
Sotalol	Sotalol Hcl	24	suppressed
Meloxicam	Meloxicam	23	13
Methimazole	Methimazole	23	suppressed
Prednisolone Acetate	Prednisolone Acetate	23	11
Thiothixene	Thiothixene	23	suppressed
Xifaxan	Rifaximin	23	suppressed
Calcitriol	Calcitriol	22	suppressed
Cephalexin	Cephalexin	22	13
Insulin Lispro	Insulin Lispro	22	11
Chlorthalidone	Chlorthalidone	21	suppressed
Incruse Ellipta	Umeclidinium Bromide	21	suppressed
Lactulose	Lactulose	21	12
Lidocaine	Lidocaine	21	14
Torsemide	Torsemide	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	21	suppressed
Heparin Sodium	Heparin Sodium,porcine	20	suppressed
Loteprednol Etabonate	Loteprednol Etabonate	20	suppressed
Glipizide Er	Glipizide	19	suppressed
Repaglinide	Repaglinide	19	suppressed
Timolol Maleate	Timolol Maleate	19	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Acetic Acid	Acetic Acid	17	suppressed
Carbamazepine	Carbamazepine	17	suppressed
Misoprostol	Misoprostol	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	11
Digoxin	Digoxin	16	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Colchicine	Colchicine	15	suppressed
Dapagliflozin	Dapagliflozin Propanediol	15	12
Erythromycin	Erythromycin Base	15	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	15	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	11
Levofloxacin	Levofloxacin	15	13
Novolog Flexpen	Insulin Aspart	15	12
Oseltamivir Phosphate	Oseltamivir Phosphate	15	12
Risedronate Sodium	Risedronate Sodium	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	11
Hydroxyurea	Hydroxyurea	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Nystop	Nystatin	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Scopolamine	Scopolamine	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Admelog Solostar	Insulin Lispro	13	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Arformoterol Tartrate	Arformoterol Tartrate	13	suppressed
Azithromycin	Azithromycin	13	suppressed
Cyclosporine	Cyclosporine	13	suppressed
Galantamine Hbr	Galantamine Hbr	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Insulin Glargine Solostar	Insulin Glargine,hum.Rec.Anlog	13	11
Lurasidone Hcl	Lurasidone Hcl	13	suppressed
Morphine Sulfate	Morphine Sulfate	13	12
Novolog	Insulin Aspart	13	suppressed
Sevelamer Hcl	Sevelamer Hcl	13	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Kapspargo Sprinkle	Metoprolol Succinate	12	suppressed
Naproxen	Naproxen	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Silodosin	Silodosin	12	suppressed
Sps	Sodium Polystyrene Sulfon/Sorb	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Glucagon Emergency Kit	Glucagon	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Juluca	Dolutegravir/Rilpivirine	11	suppressed
Lacosamide	Lacosamide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$7,743.88 · 13 records	Lilly USA, LLC	AIRSUPRA, DUPIXENT, KRYSTEXXA, MOUNJARO	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error